帕博利珠单抗在HIV感染合并晚期癌症患者中的安全性评估——一项1期研究
这项开放标签、非随机、1期多中心研究在7个癌症免疫治疗试验网络站点纳入30例HIV感染合并晚期癌症患者,评估帕博利珠单抗(200 mg静脉注射,每3周一次,最多35剂)的安全性。结果显示安全性可接受,HIV得到控制,但1例治疗前KSHV病毒血症患者发生多克隆KSHV相关B细胞增殖并死亡;肺癌、非霍奇金淋巴瘤和卡波西肉瘤中可见临床获益。
要点
- 帕博利珠单抗在CD4+ T细胞计数大于100个/μL且接受ART的HIV合并晚期癌症患者中安全性可接受。
- 帕博利珠单抗可能与KSHV相关B细胞增殖有关,1例治疗前KSHV病毒血症患者因此死亡。
- 肺癌、非霍奇金淋巴瘤和卡波西肉瘤中观察到临床获益。
核心结论
- 帕博利珠单抗在HIV感染合并晚期癌症、接受ART且CD4+ T细胞计数大于100个/μL的患者中安全性可接受,但可能与KSHV相关B细胞增殖有关。
- 在肺癌、非霍奇金淋巴瘤和卡波西肉瘤中观察到临床获益。
- 抗PD-1治疗适用于该人群中美国食品药品监督管理局批准的适应证和临床试验。
研究设计与样本
- 开放标签、非随机、1期多中心研究,在7个癌症免疫治疗试验网络站点开展。
- 纳入HIV感染合并晚期癌症、CD4计数大于或等于100个/μL、接受抗逆转录病毒治疗(ART)4周或以上、HIV病毒载量小于200拷贝/mL的患者。
- 排除标准包括未控制的乙型或丙型肝炎感染、活动性免疫抑制治疗或需全身治疗的自身免疫性疾病史。
- 帕博利珠单抗200 mg静脉给药,每3周一次,最多35剂,按CD4计数分为3个队列;参与者继续ART。
- 2016年4月至2018年3月共纳入30例参与者(28例男性、2例女性;中位[范围]年龄57[39-77]岁)。
主要发现
- 6例为卡波西肉瘤(KS),5例为非霍奇金淋巴瘤(NHL),19例为非AIDS定义性癌症。
- 在183个帕博利珠单抗治疗周期中观察安全性;至少可能归因于帕博利珠单抗的治疗中出现不良事件大多为1级或2级(n=22),20%(n=6)为3级。
- 免疫相关临床关注事件(irECI)包括甲状腺功能减退(6例)、肺炎(3例)、皮疹(2例)、转氨酶/丙氨酸氨基转移酶升高(1例)和肌肉骨骼事件(1例)。
- 1例治疗前KS疱疹病毒(KSHV)病毒血症的参与者发生多克隆KSHV相关B细胞增殖并死亡;所有参与者HIV均得到控制。
- CD4计数增加未达统计学显著(中位增加19个/μL;P=0.18)。
关键数值与推荐
- 安全性采用现行NCI常见不良事件术语标准评估;2级或以上的免疫相关不良事件被视为免疫相关临床关注事件(irECI)。
- 肿瘤疗效采用标准肿瘤特异性标准评估。
临床怎么用
- 抗PD-1治疗适用于该人群中美国食品药品监督管理局批准的适应证和临床试验。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Anti-PD-1 (anti-programmed cell death 1) and anti-PD-L1 (anti-programmed cell death ligand 1) regimens are preferred therapies for many cancers, including cancers associated with HIV. However, patients with HIV were excluded from most registered trials. OBJECTIVE: The primary objective was to evaluate the safety of pembrolizumab in people with HIV and advanced cancer; the secondary objective was to evaluate tumor responses. DESIGN, SETTING, AND PARTICIPANTS: Open-label, nonrandomized, phase 1 multicenter study conducted at 7 Cancer Immunotherapy Trials Network sites. Patients with HIV and advanced cancer as well as a CD4 count greater than or equal to 100 cells/μL, antiretroviral therapy (ART) for 4 or more weeks, and an HIV viral load of less than 200 copies/mL were eligible. Exclusion criteria included uncontrolled hepatitis B or C infection, active immunosuppressive therapy, or a history of autoimmune disease requiring systemic therapy. INTERVENTIONS: Pembrolizumab, 200 mg, administered intravenously every 3 weeks for up to 35 doses in 3 CD4 count-defined cohorts. Participants continued ART. MAIN OUTCOMES AND MEASURES: Safety and tolerability were assessed using current NCI Common Terminology Criteria for Adverse Events. Immune-related adverse events grade 2 or higher were considered immune-related events of clinical interest (irECI). Tumor responses were evaluated using standard tumor-specific criteria. RESULTS: Thirty participants (28 men and 2 women; median [range] age, 57 [39-77] years) were enrolled from April 2016 through March 2018; 6 had Kaposi sarcoma (KS), 5 had non-Hodgkin lymphoma (NHL), and 19 had non-AIDS-defining cancers. Safety was observed over 183 cycles of treatment with pembrolizumab. Most treatment-emergent adverse events at least possibly attributed to pembrolizumab were grade 1 or 2 (n = 22), and 20% (n = 6) were grade 3. The irECI included hypothyroidism (6 participants), pneumonitis (3 participants), rash (2 participants), an elevated aminotransferase/alanine aminotransferase level (1 participant), and a musculoskeletal event (1 participant). One participant with pretreatment KS herpesvirus (KSHV) viremia developed a polyclonal KSHV-associated B-cell lymphoproliferation and died. HIV was controlled in all participants. Increases in CD4 count were not statistically significant (median increase, 19 cells/μL; P = .18). Best tumor responses included complete response (lung, 1 patient), partial response (NHL, 2 patients), stable disease for 24 weeks or more (KS, 2 patients), stable disease for less than 24 weeks (15 patients), and progressive disease (8 patients); 2 patients were not evaluable. CONCLUSIONS AND RELEVANCE: Pembrolizumab has acceptable safety in patients with cancer, HIV treated with ART, and a CD4+ T-cell count of greater than 100 cells/μL but may be associated with KSHV-associated B-cell lymphoproliferation. Clinical benefit was noted in lung cancer, NHL, and KS. Anti-PD-1 therapy is appropriate for US Food and Drug Administration-approved indications and clinical trials in this population. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT02595866.
引用
- Uldrick TS, Gonçalves PH, Abdul-Hay M, et al. Assessment of the Safety of Pembrolizumab in Patients With HIV and Advanced Cancer-A Phase 1 Study. JAMA Oncol. 2019. PMID: 31154457. doi:10.1001/jamaoncol.2019.2244
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。